Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy.

Abstract

Abdominopelvic irradiation was given to 18 stage II-IV ovarian carcinoma patients who completed cisplatinum-based combination chemotherapy, were in complete clinical remission, and who underwent second-look laparotomy. The survival as well as the progression-free interval (PFI) was significantly longer in patients with a negative second-look laparotomy than in those with limited residual disease at this operation. Abdominopelvic irradiation was not effective in patients with limited residual disease at second-look laparotomy (3 year survival--34.3% and median PFI from second-look laparotomy--4.8 months). Even in patients with a negative second-look laparotomy the median PFI was only 13 months from this operation and the 3-year survival was 87.5%. The results were similar to other comparable series in which no treatment was administered to patients with a negative second-look laparotomy.

• Authors: J Menczer, M Modan, J Brenner, G Ben-Baruch, H Brenner
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 24 Issue 2 Pg. 149-54 (Jun 1986) ISSN: 0090-8258 [Print] United States
• PMID: 3710262 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Doxorubicin
• Cyclophosphamide
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Laparotomy
• Middle Aged
• Ovarian Neoplasms (drug therapy, mortality, radiotherapy)
• Postoperative Care
• Probability
• Reoperation
• Time Factors